News Release

Presentation of Stroma Liquid Biopsy at the US Human Proteome Annual Conference

MONMOUTH JUNCTION, NJ, March 28, 2018 -- Biotech Support Group reports on recent research, presented as a poster report and highlighted as a speaker presentation at the 14th Annual US HUPO Conference, held March 11-14, 2018 in Minneapolis, Minnesota USA. This research shows that through robust quantitative mass spectrometry workflows, systemic response to the presence of cancer can be profiled with protein biomarkers. These biomarkers fall within three common pathways which change in the bloodstream regardless of the primary tumor, stage, metastatic disease, or tumor burden. Five different cancers – lung, breast, pancreatic, lymph and ovary, were profiled along with normal/healthy individuals of approximate age and matched sex for comparison.

The presentation was entitled “Stroma Liquid Biopsy – Pan-Cancer Dysregulation of the Serum Proteome”. It can be downloaded at: http://www.biotechsupportgroup.com/v/vspfiles/templates/257/pdf/USHUPO2018PosterPrintVersion.pdf

"After several years of optimizing our AlbuVoid™ bead based enrichment methods and aggregating our data, I am very pleased that we can report what we believe are significant discoveries. Our selection of biomarkers offer key advantages as they are all highly observable, being of relative high abundance in the bloodstream. Furthermore, they are all highly differentiated – many severely, in the cancer population, and very stable in the normal/healthy population. Under the guidance of a physician, such dysregulated patterns may serve within the context of current ‘liquid biopsy’ platforms, forming an early indicator for cancer even before clinical evidence. These same patterns may be prognostic as well as offer individualized and precision therapy for a patient. We hope to refine our reporting methods with additional investigations in the future. For this, we are engaging partnerships with organizations to commercialize our proprietary discoveries, so ultimately we can improve cancer patient outcomes.”, states Dr. Swapan Roy, Ph.D., President and Founder of Biotech Support Group. 

For more information on AlbuVoid™, go to: http://www.biotechsupportgroup.com/AlbuVoid-Albumin-Depletion-and-Low-Abundance-p/avk.htm

About Biotech Support Group LLC

Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for these expanding markets. Following a tiered business strategy, the company continues its growth in the consumable research products area supporting the rapidly expanding installation of LC-MS instrument and computational infrastructure. For this market, key products include: AlbuVoid™ and AlbuSorb™ for albumin depletion, Cleanascite™ for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal, and NuGel™ for functional proteomics. From these innovations, the company has acquired knowledgebase and biomarker intellectual property assets that support discoveries of protein markers from blood, with special emphasis on early detection and personalized medical decisions for cancer patients. For more information, go to http://www.biotechsupportgroup.com

Contact: Matthew Kuruc 732-274-2866 mkuruc@biotechsupportgroup.com